HLXB
Income statement / Annual
Last year (2024), BridgeBio Oncology Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, BridgeBio Oncology Therapeutics, Inc.'s net income was $7.60 M.
See BridgeBio Oncology Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$584.39 K
|
$0.00
|
$0.00
|
$74.33 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$584.39 K
|
$0.00
|
$0.00
|
$43.36 K
|
| Other Expenses |
$0.00
|
$41.69 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$584.39 K
|
$41.69 K
|
$3.52 K
|
$43.36 K
|
| Cost And Expenses |
$584.39 K
|
$41.69 K
|
$3.52 K
|
$43.36 K
|
| Interest Income |
$8.46 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| EBITDA |
$7.60 M |
-$41.69 K |
-$3.52 K |
-$43.36 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$8.18 M
|
$0.00
|
$0.00
|
$3.00
|
| Income Before Tax |
$7.60 M
|
-$41.69 K
|
-$3.52 K
|
-$43.36 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
$7.60 M
|
-$41.69 K
|
-$3.52 K
|
-$43.36 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
| EPS |
0.46 |
-0.002 |
0 |
-0.0021 |
| EPS Diluted |
0.46 |
-0.002 |
0 |
-0.0021 |
| Weighted Average Shares Out |
$16.64 M
|
$20.49 M
|
$20.49 M
|
$20.49 M
|
| Weighted Average Shares Out Diluted |
$16.64 M
|
$20.49 M
|
$20.49 M
|
$20.49 M
|
| Link |
|
|
|
|
